A major public health concern for our age is the increasing resistance to antibiotics. The U.K. government recently commissioned a review under Jim O'Neill^[@ref1]^ that examined this issue in depth and proposed structural changes to industry practice, drug pricing, etc. in an attempt to redirect resources to the problem. Similarly, in the United States, the CARB-X^[@ref2]^ initiative, a jointly funded public-private partnership between the Wellcome Trust and BARDA,^[@ref3]^ is revitalizing research in this area through various funding initiatives. In particular, Gram-negative bacteria are becoming a major concern because not only are they inherently more difficult to treat with antibiotics due to entry and efflux issues but also the crucial carbapenem class of β-lactam antibiotics is becoming less clinically effective. As a consequence, major Gram-negative pathogens are currently evolving toward pan-drug-resistant phenotypes, whose potential global spread may lead to a dramatic return to the pre-antibiotic era. A major resistance mechanism to β-lactams antibiotics is represented by the production of one or more β-lactamase enzymes, which efficiently hydrolyze the amide bond of the β-lactam ring. β-Lactamases belong to two structurally and mechanistically unrelated families of enzymes,^[@ref4]^ the serine-β-lactamases (SBLs; classes A, C, and D), which use an active serine to cleave the β-lactam in a covalent mechanism, and the metallo-β-lactamases (MBLs; class B), which use metal ion catalysis to directly hydrolyze the β-lactam without the formation of a covalent intermediate. To counter the threat of emerging resistance, the *Streptomyces clavuligerus* natural product clavulanic acid (**2**), an SBL inhibitor ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), was introduced in 1981 as part of a combination together with the β-lactam antibiotic amoxicillin (as Augmentin),^[@ref5]^ followed by tazobactam in 1992, combined with piperacillin.^[@ref6]^ More recently, there has been renewed interest in the field of β-lactamase inhibitor discovery to counter the threat from newer β-lactamases, which are not inhibited by clavulanic acid or tazobactam, such as the extended spectrum β-lactamases (ESBLs) and carbapenemases. This has led to the development of two new synthetic classes of inhibitors, namely the diazabicyclooctane (DBO) series, as exemplified by avibactam^[@ref7]^ (**3**), which is used in combination with ceftazidime, and the boronates of generalized bicyclic structure (**4**) plus monocyclic boronate vaborbactam^[@ref8]^ (**5**), which is used in combination with meropenem. However, both **3** and **5** are exclusively SBL inhibitors, whereas examples of generalized structure (**4**) are known to have dual SBL and MBL inhibitory activity,^[@ref9]^ a novel finding that can be rationalized at the molecular level.^[@ref10]^ However, as of yet, there are no MBL inhibitors in clinical use despite there being a clear unmet medical need.^[@ref11]^

![Representative Examples of β-Lactamase Inhibitors: (1) Pyridine-2-carboxylic Acid (Picolinic Acid), (2) Clavulanic Acid, (3) Avibactam, (4) Generalized Cyclic Boronate, (5) Vaborbactam, and (6) 2,6-Pyridine Dicarboxylic Acid Derivative](id-2018-002469_0007){#sch1}

The MBL family includes the clinically relevant B1 subfamily containing the acquired IMP, VIM, and NDM subgroups of allelic variants. Many classes of MBL inhibitors have been reported in the research stage including bisthiazolidines, thiols, tetrazoles, succinic acids, and hydroxamates.^[@ref12]^

Recently Chen et al.^[@ref13]^ reported novel MBL inhibitors (as exemplified by **6**) based on a pyridine-2-carboxylic acid (**1**) scaffold, which was previously reported to be a modest inhibitor of the *Aeromonas hydrophila* CphA MBL (*K*~i~ \[inhibition constant\] = 6 μM).^[@ref14]^ The CphA enzyme belongs to the divergent B2 subclass of MBLs, which have a single Zn ion in their active site and do not have the clinical significance of subclass B1 MBLs (which instead coordinate two Zn ions in the di-nuclear active site). These compounds have promising activity in terms of both NDM-1 inhibition and potentiation against clinical strains expressing NDM-1; however, the most-active compound from this work (compound **6** in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) contains a lipophilic aniline, a moiety well-known to be associated with clastogenic and carcinogenic effects.^[@ref15]^

In this study, we also report on the design and optimization of new MBL inhibitors starting from pyridine-2-carboxylic acid; however, we have taken a very different medicinal chemistry approach, leading to the identification of a chemically distinct series with promising activity against MBL-producing clinical isolates and drug-like properties, which makes it suitable for further pharmaceutical development.

Results and Discussion {#sec2}
======================

Derivatives of Pyridine-2-carboxylic Acid, Pan-MBL Inhibitors {#sec2.1}
-------------------------------------------------------------

Although the biological activity of pyridine-2-carboxylic acid (**1**) is relatively modest, its low molecular weight and simple structure makes it an attractive starting point for medicinal chemistry. From the work of Horsfall et al.,^[@ref14]^ biochemical and structural analyses clearly demonstrated that pyridine-2-carboxylic acid (**1**) was a competitive inhibitor of CphA. This mechanism of inhibition, relying on the formation of a stable enzyme--inhibitor complex, was different from that exhibited by its close bidentate analogue 2,6-dipicolinic acid, which instead acts as a strong zinc chelator and non-specifically inactivates metallo-enzymes. The latter mechanism of action, also shown by EDTA^[@ref16]^ and some natural products,^[@ref17]^ may produce significant off-target implications in clinical use^[@ref18]^ and be less effective against newer NDM variants, which have evolved high-affinity Zn-binding and are therefore less prone to inhibition by metal-chelating agents.^[@ref19]^ Using enzyme assays, we evaluated the potential of **1** to inhibit MBLs other than CphA and were encouraged to find that it exhibited an IC~50~ value of 17 μM against NDM-1, although there was no significant activity against VIM-1 or IMP-1 enzymes. However, **1** showed no reduction of imipenem MIC when tested at concentrations up to 1 mM on a laboratory strain of NDM-1-producing *Escherichia coli* (DH5α/pLBII-NDM-1), presumably due to lack of penetration into, or efflux from, the periplasm (data not shown).

Because the X-ray structure of 2,4-pyridine dicarboxylic acid in the MBL CphA clearly shows coordination of both the carboxylate group at position 2 and the pyridine nitrogen to the single Zn ion, coordinated by conserved residues Asp120, Cys221, and His263, which form the so-called "Zn2" site ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), we screened a number of related heterocyclic acids with this structural feature. The modest inhibition of NDM-1 was seen with quinoline acid (**7**) and isoquinoline acid (**11**), but no inhibition of the other two MBLs was detected at concentration as high as 200 μM. Surprisingly, other heterocyclic acids such as imidazole (**8**), pyrazine (**9**), and pyridazine (**10**) showed no detectable inhibition. Given the simplicity of the chemistry, compared with both the quinoline and isoquinoline series, we considered pyridine-2-carboxylic acid (**1**) to be a suitable starting point for a medicinal chemistry program. Initially, this involved some array chemistry, adding substituents to ethylpyridine-2-carboxylate followed ester hydrolysis to give the acid ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The short-term objective was to improve the inhibition spectrum of the molecule and obtain whole cell synergistic activity, with the longer-term objective being the discovery of a drug molecule with good PK and efficacy.

![Mode of binding of 2,4-pyridine dicarboxylic acid (green) in the active site of CphA (PDB code 2GKL) showing the coordination to the single Zn ion.](id-2018-002469_0001){#fig1}

![General Synthetic Routes Used to Prepare Compounds Based on the Pyridine-2-carboxylic Acid Scaffold\
(a) R~1~CO~2~H, HATU, Et~3~N, then LiOH; (b) R~2~SO~2~Cl, Et~3~N, then LiOH; (c) ArB(OH)2 and (Ph~3~P)~4~P, then LiOH; (d) R~3~NH~2~, HATU, Et~3~N, then LiOH.](id-2018-002469_0008){#sch2}

We used standard synthetic routes to explore the activity of biaryl analogues, amides, and sulfonamides at all available positions of the parent structure **1** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} and [Supplementary Data](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.8b00246/suppl_file/id8b00246_si_001.pdf)). These array compounds were screened against a panel of NDM-1, VIM-1, VIM-2, and IMP-1 enzymes. In terms of relative importance, we were most interested in NDM-1 and VIM-1 because of their widespread prevalence in *Enterobacteriaceae* (IMP-1 is not so widespread geographically, and VIM-2 is almost exclusively found in *Pseudomonas*).^[@ref20]^ The results of this initial array work are reported in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Compounds of interest were progressed to a whole-cell meropenem potentiation assay to investigate if the inhibitor could restore the antibacterial activity of meropenem against resistant strains, where the resistance was attributable to the production of an MBL enzyme. Initially, we used laboratory strains transformed with plasmids expressing only the MBL resistance genes; however, early on, we switched to using clinical carbapenem-resistant *Enterobacteriaceae* (CRE) isolates to evaluate the synergistic activity of the compounds because these presented a greater challenge that was more representative of the clinical situation.

###### Selected Pyridine-2-carboxylate Analogues (Full Table Can Be Found in the [Supplementary Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.8b00246/suppl_file/id8b00246_si_001.pdf))[a](#tbl1-fn1){ref-type="table-fn"}

![](id-2018-002469_0009){#gr9}

All IC~50~ values reported herein are the average of at least two independent assays. All reported IC~50~ values have *R*^2^ values of \>0.95 of the fitting curve.

Biaryl analogues such as compounds **12** to **16** were essentially inactive and were not pursued further. Encouragingly, amide groups were tolerated with respect to NDM-1 inhibition at all four positions on the pyridine ring. One of the earliest compounds prepared, amide **17**, showed the promising low micromolar inhibition of NDM-1 as well as detectable inhibition of all three enzymes at higher concentrations, representing an interesting, although modest, broad-spectrum inhibitor. Related amides such as **18** proved, by contrast, inactive at a concentration of up to 200 μM on all tested enzymes, whereas **17** and **23** represented a significant advance from **1**, which only had modest activity against the NDM-1 enzyme.

We also explored the sulfonamide substituent because, due to the different hybridization state of the sp3 sulfur compared to sp2 carbon, sulfonamides access alternative regions of space and H-bonding opportunities as compared with the amides. Surprisingly strong inhibition of VIM-2 was observed by certain sulfonamides such as **32** and **43**. The modest but genuine MBL inhibition achieved against both NDM-1 and VIM-1 represented a significant advance over the starting position of **1**, stimulating further efforts to improve the potency and spectrum of the series.

X-ray Crystallography Revealing of a Novel Binding Mode to the VIM-2 MBL {#sec2.2}
------------------------------------------------------------------------

The mode of binding of certain inhibitors was ascertained by X-ray crystallography experiments. A crystal structure of VIM-2 in complex with the simple phenyl sulfonamide **32** revealed interesting features of its binding modality ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Notably the pyridine nitrogen and the carboxylate group of the inhibitor were bound to a single Zn atom (Zn2, coordinated by conserved residues Asp120, Cys221, and His263). Inhibitor binding also resulted in the displacement of two crystallographic water molecules found in the native structure but, interestingly, not the so-called "bridging" water molecule coordinated by the two active site Zn ions, which provides the nucleophile attacking the carbonyl carbon of the β-lactam substrate. Taken with the enzyme inhibition data, this structural information is fully in accord with a reversible competitive mode of action and not a general chelation effect (whereby the ligand removes metal ions from solution eventually stripping metal ions from the enzyme through equilibrium processes). Although inhibitor binding did not alter the tertiary structure of the enzyme, several side chains movements were observed, such as the Arg228 side chain being displaced by 2.7 Å to create a strong salt-bridge interaction with inhibitor carboxylate, while the side chain of Tyr67 was folded over deeper into the active site cavity (∼60°) and rotated (∼75°) to align with the inhibitor's phenyl moiety and create a strong aromatic interaction. Additional interactions were found to stabilize inhibitor binding, including a H-bond involving one sulfonamide oxygen with the backbone nitrogen of Asn233, a residue conserved in all subclass B1 MBLs and whose role is critical to properly orient the β-lactam substrate.

![X-ray structure of VIM-2 inhibited by **32**. (A) Close view of the VIM-2 active site (protein secondary structure elements and the active-site residues are shown in green, surrounded by the 2*F*~o~--*F*~c~ Fourier map, blue meshes, contoured at 2 σ) in complex with compound **32** (shown in cyan and surrounded by the omit *F*~o~--*F*~c~ map, green meshes, contoured at 3 σ). (B) Close-up view of the VIM-2 active site showing the network of interactions between the inhibitor (cyan), the Zn2 ion and residues Arg228 and Asn233. (C) Orthogonal view of panel B and superimposition with the VIM-2 native structure (PDB code 1KO3, orange) showing the significant movements of the side chains of residues Phe61, Tyr67, and Arg228 (green sticks) upon the binding of **32** (cyan).](id-2018-002469_0002){#fig2}

Scaffold-Hopping from Pyridine to Thiazole and Considerable Activity Improvement {#sec2.3}
--------------------------------------------------------------------------------

As mentioned above, as part of the initial chemistry exploration, we investigated alternatives to the pyridine ring while keeping a "pyridine-like" nitrogen adjacent to the carbon bearing the carboxy group. Several different heterocyclic replacements in combination with the best side chains were explored. All but one of the potential heterocyclic replacements showed worse activity than pyridine (data not shown); however, encouragingly, the thiazole analogues showed a significant and consistent improvement over the corresponding pyridine analogues, in terms of both in vitro enzyme inhibition and whole-cell meropenem potentiation ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"})

###### Comparison of IC~50~ Values and Meropenem Potentiation Data for Matched Pairs of Pyridyl (A) and Thiazolyl (B) Analogues

![](id-2018-002469_0010){#GRAPHIC-d7e903-autogenerated}

![](id-2018-002469_0011){#gr10}

NDM-1-producing strain *Escherichia coli* NTBC121 (MIC~MEM~, 32 μg/mL).

VIM-1-producing strain *Klebsiella pneumoniae* NTBC055 (MIC~MEM~, 16 μg/mL).

IMP-1-producing strain *K. pneumoniae* NTBC062 (MIC~MEM~, 4 μg/mL).

The inhibitor was present at 100 μM.

![Comparison of NDM-1 IC~50~ values for matched pairs of pyridyl (blue) and thiazolyl (green) analogues.](id-2018-002469_0003){#fig3}

![Comparison of meropenem potentiation data for matched pairs of pyridine (blue) and thiazole (green) analogues.](id-2018-002469_0004){#fig4}

Several points emerge from this SAR analysis. First, trends are easier to identify in the activity observed against NDM-1 clinical strains because these are generally much more resistant than VIM-1- or IMP-1-producing clinical strains,^[@ref19]^ and hence, there is a bigger window in which to observe changes in activity. Second, it is difficult to determine whether improvements are due solely to changes in enzyme inhibition or also due to better penetration into (or lack of efflux from) the periplasm. To help identify compounds that have an improved ability to penetrate into bacterial cells we have defined a new term we call the "potentiation efficiency" (PE) for each compound. This empirical term is calculated by dividing the potentiated MIC for an MBL-producing strain by the IC~50~ for the respective purified enzyme (PE = MIC/IC~50~), thus "normalizing" the whole cell potentiation with respect to enzyme activity such that the smaller the PE the better a compound is accessing the periplasm, independent of the actual enzyme inhibition. For example, if we consider the matched pair of **61** (pyridyl) and **62** (thiazolyl) analogues, then it is clear that the thiazolyl derivative has improved NDM-1 enzyme inhibitory activity (IC~50~ 4.5 μM versus 49.9 μM) and also improved meropenem potentiation against a corresponding NDM-1 strain (MIC 0.125 μg/mL versus 16 μg/mL). The corresponding PE values for **61** and **62** are 0.32 and 0.027, respectively, showing that in this instance there is a 10-fold improvement in potentiation over and above what might be expected from the increase in enzyme inhibition alone, suggesting that introduction of the thiazole has a profound effect on both enzyme inhibition and bacterial penetration. Although we are using this metric in the situation in which the inhibitors have no intrinsic antibacterial activity, in principle, the PE function should have wide applicability in antibacterial research in which penetration into the periplasm or the cytoplasm is a prerequisite for antibacterial action. The limitation, of course, is that it does not give information as to whether penetration or efflux is an issue but it can be a useful empirical tool to facilitate SAR analysis and the direction of the medicinal chemistry. The reason for the differences between pyridyl and thiazolyl analogues is unclear at this juncture.

A crystal structure of VIM-2 in complex with thiazole (**62**) was also obtained, which confirmed a similar mode of inhibitor binding as **32**, with the thiazole nitrogen atom interacting exclusively with Zn2 ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}) and the carboxylate interacting with both Arg228 and Zn2. However, the substituted sulfonamide has adopted a slightly different conformation compared to that observed in the complex with (**32**) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). In this alternative binding mode, one oxygen atom of the sulfonamide linker still interacts with the backbone nitrogen of Asn233 but the phenyl group is interacting with Phe61 instead of Tyr67. The side chain of the latter occupies a position similar to that found in the native structure, while Phe61 is slightly rotated and displaced upon binding of **62**.

![X-ray structure of VIM-2 inhibited by **62**. (A) Close view of the VIM-2 active site (protein secondary structure elements and the active site residues are shown in blue, surrounded by the 2*F*~o~--*F*~c~ Fourier map, blue meshes, contoured at 2 σ) in complex with **62** (shown in magenta and surrounded by the omit *F*~o~--*F*~c~ map, green meshes, contoured at 3 σ). (B) Binding of **62** in the enzyme active site relies on a similar set of interactions between the thiazole moiety, Zn2, and the Arg228 side chain. (C) Comparison of the substituted sulfonamide conformation of **62**, thiazole (magenta) and **32**, pyridine (cyan); the position of Phe61 and Tyr67 in the native VIM-2 is shown in orange.](id-2018-002469_0005){#fig5}

Moving from Phenyl Sulfonamide to Pyridyl Sulfonamide and Improvement of Solubility of the Acid Form {#sec2.4}
----------------------------------------------------------------------------------------------------

Alongside improving compound activity, we also focused on improving the physicochemical profile and in particular aqueous solubility. The aqueous solubility of the key compound **62** was determined as 1.1 mg/mL, whereas a solubility of at least 10 mg/mL would be required to deliver a therapeutically effective intravenous dose in an acceptable volume of the aqueous vehicle. A standard approach to increasing polarity and aqueous solubility is to add nitrogen atoms into a phenyl ring. Consequently, we prepared a small set of analogues set of side-chain pyridyl analogues of **62**. A total of two of the three aza analogues had improved enzyme inhibition against NDM-1 ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), and furthermore, the most active compound (**76**) facilitated a meropenem MIC of 0.06 μg/mL against one of our NDM-1 producing clinical strains (*E. coli* NTBC121) when tested in the presence of 100 μM inhibitor compared to an MIC of 0.125 μg/mL for **62**. The solubility of the side-chain pyridyl analogue (2.4 mg/mL) was double that of the phenyl analogue **62**, and conversion to the sodium salt improved the solubility to almost 20 mg/mL ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), achieving the target solubility for testing in animal efficacy studies.

###### Enzyme Inhibition, Potentiation, and Solubility of Side-Chain Phenyl and Pyridyl Analogues

![](id-2018-002469_0012){#GRAPHIC-d7e1091-autogenerated}

  compound   X    Y    Z    NDM-1 IC~50~ μM (MEM MIC, μg/mL)[a](#t3fn1){ref-type="table-fn"}   VIM-1 IC~50~ μM   IMP-1 IC~50~ μM   VIM-2 IC~50~ μM   solubility, mg/mL[b](#t3fn2){ref-type="table-fn"} (Na salt)
  ---------- ---- ---- ---- ------------------------------------------------------------------ ----------------- ----------------- ----------------- -------------------------------------------------------------
  **75**     N    CH   CH   12.9                                                               \>200             113.7             16.1              N/D
  **76**     CH   N    CH   2.67 (0.06)                                                        \>200             54.0              6.7               2.4 (16.9)
  **77**     CH   CH   N    3.4                                                                180               23.4              1.8               ND
  **62**     CH   CH   CH   4.5 (0.125)                                                        \>200             58.2              6.2               1.1 (18.9)

NDM-1-producing strain *E. coli* NTBC121 (MEM MIC, 32 μg/mL). The inhibitor was present at 100 μM.

Solubility was determined in phosphate-buffered saline (PBS) at pH 7.4.

The X-ray structure of VIM-2 bound to (**76**) showed a broadly similar set of interactions to that of compounds **32** and **62** ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}), with the sulfonamide substituent located between residues Phe61 and Tyr67, inducing a significant rotation of the side chain of the latter. Overall, these structural data, which highlight a salt bridge interaction between the negatively charged carboxylate group of the inhibitor and the positively charged side chain of Arg228 could provide, to some extent, a rationale for the overall lower activity of these compounds ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) on VIM-1. Indeed, Arg228 (whose role can be assumed by Lys224 present in NDM-1 and IMP-1) is replaced by a serine residue in VIM-1, in which this interaction will be very likely abolished.

![X-ray structure of VIM-2 inhibited by **76**. (A) Close view of the VIM-2 active site (protein secondary structure elements and the active site residues are shown in pink, surrounded by the 2*F*~o~--*F*~c~ Fourier map, blue meshes, contoured at 2 σ) in complex with **62** (shown in green and surrounded by the omit *F*~o~--*F*~c~ map, green meshes, contoured at 3 σ). (B) Close view of the VIM-2 active site (pink) inhibited by **76** (light green). (C) Overlay of inhibitors **32** (cyan), **62** (magenta), and **76** (light green) in the VIM-2 active site, showing the conserved interactions between the inhibitor and Zn2, Arg228, and Asn233; the binding of **76** also induces the rotation of the Tyr67 side chain to accommodate the pyridyl sulfonamide substituent (native VIM-2 shown in orange).](id-2018-002469_0006){#fig6}

Conclusions {#sec3}
===========

Our approach to the problem of antibiotic resistance due to the emergence of MBL-producing Gram-negative pathogens has been to undertake a medicinal chemistry campaign to develop MBL inhibitors starting from pyridine-2-carboxylic acid (**1**). Early array chemistry expanded the MBL coverage from NDM-1 to encompass VIM-1, VIM-2, and IMP-1 while also introducing whole cell activity such as to restore the antibiotic activity of meropenem against clinical strains of MBL-producing *Enterobacteriaceae*. Key benefits of this approach over a nonspecific metal chelation approach (such as using EDTA) are that off-target human toxicities are minimized and the fact that newer NDM variants, due to increased Zn affinity, are less susceptible to compounds that depend on stripping Zn from the enzyme active site.^[@ref20]−[@ref22]^

A leap in both enzyme inhibition and potentiation was achieved by switching from pyridine to the thiazole scaffold. As shown from its increased PE value, the thiazolyl series exhibits improved penetration into the bacterial periplasm as well as improved enzyme inhibition. Additionally, although a modest improvement to kinetic solubility was obtained by moving from a side-chain phenyl sulfonamide to a side-chain pyridyl sulfonamide, greater improvements were achieved on making the sodium salt, enabling formulation at sufficiently high concentrations in aqueous buffers to perform efficacy testing in animal models. Full biological characterization of compound (**76**) (designated as **ANT431**) has recently been reported elsewhere, demonstrating it to potentiate meropenem activity against a panel of 94 randomly selected NDM- and VIM-producing clinical strains and restore the efficacy of meropenem in an *E. coli* (IR3) murine thigh infection model.^[@ref23]^ It should be pointed out that the potentiation of meropenem by ANT431 is reported here at 100 μM inhibitor concentration because that was the concentration we routinely operated at during the early stages of this project. In fact, ANT431 is effective at 28 μM (8 μg/mL).^[@ref23]^ Further research is underway to optimize this promising chemical series and deliver a preclinical development candidate.

Methods and Materials {#sec4}
=====================

Antimicrobial Susceptibility Testing {#sec4.1}
------------------------------------

Minimal inhibitory concentrations (MIC) were determined using the Clinical Laboratory Standards Institute (CLSI) broth microdilution procedure. MBL-positive *Enterobacteriaceae* clinical isolates tested in the susceptibility study included NDM-1-producing strain *E. coli* NTBC121, VIM-1-producing strain *K. pneumoniae* NTBC055, and IMP-1-producing strain *K. pneumoniae* NTBC062. (Individual MICs for all strains tested are presented in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [Table 1 in the Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.8b00246/suppl_file/id8b00246_si_001.pdf)).

In Vitro Enzyme Inhibition Assays {#sec4.2}
---------------------------------

Inhibition against purified MBLs^[@ref24]^ were determined by following hydrolysis of 300 μM imipenem in 10 mM HEPES (pH 7.5) buffer (25 °C) in the presence of 0.025 to 500 μM inhibitor using a PerkinElmer Envision (UV absorbance: 290 nm). Percentage of enzymatic inhibition is calculated for each concentration tested and reported on a nonlinear regression versus the logarithmic concentration of inhibitors. The IC~50~ value is determined from the regression curve only when the *R*^2^ of the fitting curve is \>0.95. The average of a minimum of at least 2 replicates is therefore reported.

Kinetic Solubility {#sec4.3}
------------------

This was determined by vigorous stirring (1200 rpm) of a 20 mg/mL mixture of the test compound in phosphate-buffered saline (PBS) at pH 7.4 for 4 h. The mixture was then centrifuged for 20 min at 10 000 rpm and the supernatant further processed by filtration. The concentration of the test compound in the filtrate was then determined by high-performance liquid chromatography (UV analysis) by comparison to a standard calibration curve of the test compound.

X-ray Crystallography {#sec4.4}
---------------------

The VIM-2 MBL was produced, purified, and crystallized essentially as previously described.^[@ref25],[@ref26]^ The experimental details of protein crystallization, crystal soaking, data collection, reduction, and refinement (performed using the procedures described elsewhere)^[@ref26]^ are reported in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.8b00246/suppl_file/id8b00246_si_001.pdf). Omit maps of the three inhibitors bound to VIM-2 are shown in [Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}. Coordinates and structure factors of VIM-2 in complex with inhibitors ANT-090 (**32**), ANT-330 (**62**), and ANT-431 (**76**) were deposited in the RCSB Protein Data Bank under the accession codes 5MXQ, 5MXR, and 6HF5, respectively.

### Synthesis of Sodium 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylate (ANT431, Na Salt) {#sec4.4.1}

Ethyl 5-amino-1,3-thiazole-4-carboxylate, pyridine-3-sulfonyl chloride and all other reagents and solvents were purchased and used as such. ^1^H nuclear magnetic resonance (NMR) spectra were obtained at 400 MHz in deuterated CDCl~3~ or DMSO-*d*~*6*~ solutions (reported in ppm). ^13^C NMR spectra were obtained at 100 MHz in DMSO-*d*~*6*~, When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of doublets), dt (doublet of triplets), and q (quartet). Coupling constants are reported in hertz (Hz).

### Ethyl 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylate {#sec4.4.1.1}

To a stirred suspension of sodium hydride (60% dispersion in oil) (929 mg, 23.22 mmol) in tetrahydrofuran (50 mL) was added a solution of ethyl 5-amino-1,3-thiazole-4-carboxylate (2 g, 11.61 mmol) in tetrahydrofuran (50 mL) at 0 °C under N~2~ atmosphere. The resulting reaction mixture was stirred for 30 min at 0 °C and then treated with pyridine-3-sulfonyl chloride (2.47 g, 13.93 mmol) in tetrahydrofuran (3 mL) in a drop-wise manner at 0 °C. The resulting reaction mixture was stirred at room temperature for 3 h, then quenched with ice, diluted with water, and washed with 50% ethyl acetate in hexane (100 mL). The aqueous layer was separated, neutralized with 1 N HCl solution, and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered, and concentrated to obtain the crude product. This was purified by column chromatography on silica gel using 1--10% methanol in dichloromethane (Rf 0.1 with 10% methanol in dichloromethane) as eluent to give the title compound as a yellow solid (1.0 g, 27%). ^1^H NMR (CDCl~3~, 400 MHz, δ): 10.26 (s, 1H), 9.12 (d, *J* = 2.0 Hz, 1H), 8.83 (dd, *J* = 4.8, 1.2 Hz, 1H), 8.31 (s, 1H), 8.19--8.16 (m, 1H), 7.46 (dd, *J* = 8.0, 4.8 Hz, 1H), 4.39 (q, *J* = 7.2 Hz, 2H), 1.39 (t, *J* = 7.2 Hz, 3H). *m*/*z*: 314.0 \[M + H\]^+^.

### 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylic acid (ANT431) {#sec4.4.1.2}

To a stirred solution of ethyl 5-(pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylate (1.0 g, 3.19 mmol) in a mixture of tetrahydrofuran and water (10:5 in milliliters) was added LiOH.H~2~O (1.33 g, 31.9 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 48 h and then concentrated under vacuum. The crude residue was diluted with water (30 mL) and washed with ethyl acetate (30 mL). The aqueous layer was acidified with 1 N HCl solution to pH4. The resulting precipitation was filtered and dried under high vacuum to obtain the title compound as a yellow solid (0.85g, 93%). ^1^H NMR (DMSO-*d*~*6*~, 400 MHz, δ): 8.94 (d, *J* = 2.0 Hz, 1H), 8.79 (dd, *J* = 4.8, 1.2 Hz, 1H), 8.50 (s, 1H), 8.18 (td, *J* = 8.0, 2.0 Hz, 1H), 7.61 (dd, *J* = 8.0, 4.8 Hz, 1H). *m*/*z*: 286.0 \[M + H\]^+^.

### Sodium 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylate (ANT431, Na Salt) {#sec4.4.1.3}

To a solution of 5-(pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylic acid (850 mg, 2.98 mmol) in tetrahydrofuran (20 mL) was added 0.1 M sodium hydroxide (29.8 mL, 2.98 mmol) solution and sonicated for 10 min to get a clear solution. Water (60 mL) was added, and the mixture was lyophilized to obtain the title compound as a light brown solid (890 mg, 97%) with a melting point of 297--300 °C. ^1^H NMR (DMSO-*d*~*6,*~ 400 MHz, δ**):** 13.33 (s, 1H), 8.88 (s, 1H), 8.65 (d, *J* = 4 Hz, 1H), 8.08 (d, *J* = 8 Hz, 2H), 7.49 (dd, *J* = 8.0, 4.8 Hz, 1H); ^13^C NMR (DMSO-*d*~*6*~, 100 MHz, δ**):** 163.94, 155.34, 151.77, 146.56, 140.16, 139.54, 133.88, 128.77, 123.95. *m*/*z*: 284.0 \[M -- Na\]^−^. High-resolution electrospray ionization mass spectrometry (*m*/*z*): \[M -- Na\] calcd for C~9~H~6~O~4~N~3~S~2~, 283.9794; found, 283.9735.
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CphA

:   carbapenem-hydrolyzing metallo-β-lactamase from *Aeromonas hydrophila*

MBL

:   metallo-β-lactamase

NDM

:   New Delhi metallo-β-lactamase

PE

:   potentiation efficiency

SBL

:   serine-β-lactamase

VIM

:   Verona integron-encoded metallo-β-lactamase
